SMA 200 of Exelixis, Inc.
Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
|PLPM Planet Payment, Inc.||NASDAQ > Miscellaneous > Business Services||0.48|
|TRST TrustCo Bank Corp NY||NASDAQ > Finance > Major Banks||0.48|
|SCHL Scholastic Corporation||NASDAQ > Consumer Services > Books||0.48|
|HDNG Hardinge Inc.||NASDAQ > Capital Goods > Industrial Machinery/Components||0.49|
|CLF Cliffs Natural Resources Inc.||NYSE > Basic Industries > Precious Metals||0.49|
|KL Kirkland Lake Gold Ltd.||NYSE > Basic Industries > Precious Metals||0.49|
|EXEL Exelixis, Inc.||NASDAQ > Health Care > Biotechnology: Commercial Physical & Biological Resarch||0.49|
|HCC Warrior Met Coal, Inc.||NYSE > Energy > Coal Mining||102.00|
|WTM White Mountains Insurance Group, Ltd.||NYSE > Finance > Property-Casualty Insurers||128.23|
|NVR NVR, Inc.||NYSE > Capital Goods > Homebuilding||135.95|
|SEB Seaboard Corporation||NYSEMKT > Finance > Investment Bankers/Brokers/Service||279.36|
|DCIX Diana Containerships Inc.||NASDAQ > Transportation > Marine Transportation||648.16|
|BRK-A Berkshire Hathaway Inc.||NYSE > Finance > Property & Casualty Insurance||11,356.35|